Skip to main content

Table 2 Ongoing studies with crizotinib

From: Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

NCT Number

Combination Drugs

PHASES

URL

NCT00932451

Drug: PF-02341066

Phase2

https://ClinicalTrials.gov/show/NCT00932451

NCT00932893

Drug: PF-02341066

Phase3

https://ClinicalTrials.gov/show/NCT00932893F

Drug: Pemetrexed

Drug: Docetaxel

NCT01154140

Drug: treatment

Phase3

https://ClinicalTrials.gov/show/NCT01154140

Drug: treatment

NCT01685060

Drug: LDK378

Phase2

https://ClinicalTrials.gov/show/NCT01685060

NCT01121575

Drug: PF-02341066

Phase1

https://ClinicalTrials.gov/show/NCT01121575

Drug: PF-00299804

Drug: PF-02341066

Drug: PF-00299804

NCT00965731

Drug: Erlotinib

Phase1

https://ClinicalTrials.gov/show/NCT00965731

Drug: PF-02341066

NCT02435108

Drug: crizotinib

Phase2

https://ClinicalTrials.gov/show/NCT02435108

Back to article page

Molecular Cancer

ISSN: 1476-4598